Cardiol Therapeutics (CRDL) Projected to Post Earnings on Wednesday

Key Points

• Cardiol Therapeutics (CRDL) is scheduled to report Q1 2026 results after market close on Wednesday, May 13, with analysts forecasting earnings of ($0.07) per share and a conference call set for May 14 at 4:00 PM ET.
• Last quarter the company beat estimates (reported ($0.05) vs. consensus ($0.09)), yet analysts model $0 EPS for the current and next fiscal years and assign a consensus target price of $8.50 amid mixed ratings (two Buys, one Sell; average: Hold).
• CRDL trades around $1.31 with a market cap of $146.5M and a 12‑month range of $0.88–$1.71, and recent notable institutional activity includes sizable buys by Citadel, Bank of America, Two Sigma and others; institutions own about 12.49% of the stock.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) is expected to release its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Cardiol Therapeutics to post earnings of ($0.07) per share for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. On average, analysts expect Cardiol Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cardiol Therapeutics Trading Down 1.5%

CRDL opened at $1.31 on Wednesday. The stock has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.09. Cardiol Therapeutics has a 12-month low of $0.88 and a 12-month high of $1.71. The stock has a market capitalization of $146.48 million, a P/E ratio of -4.68 and a beta of 0.77.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in Cardiol Therapeutics by 136.2% in the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company's stock worth $36,000 after purchasing an additional 15,255 shares during the period. Citadel Advisors LLC raised its holdings in Cardiol Therapeutics by 1,132.6% in the 3rd quarter. Citadel Advisors LLC now owns 463,462 shares of the company's stock worth $496,000 after purchasing an additional 425,862 shares during the period. Two Sigma Investments LP bought a new position in Cardiol Therapeutics in the 3rd quarter worth $249,000. Virtu Financial LLC bought a new position in Cardiol Therapeutics in the 3rd quarter worth $154,000. Finally, Susquehanna International Group LLP raised its holdings in Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company's stock worth $100,000 after purchasing an additional 73,375 shares during the period. Institutional investors own 12.49% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. upgraded Cardiol Therapeutics to a "strong-buy" rating in a report on Tuesday, February 3rd. Wall Street Zen upgraded Cardiol Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, April 5th. Canaccord Genuity Group reiterated a "buy" rating and issued a $8.00 price objective on shares of Cardiol Therapeutics in a report on Monday, April 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a report on Tuesday, February 10th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $8.50.

About Cardiol Therapeutics

Cardiol Therapeutics Inc NASDAQ: CRDL is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company's lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.